Seres Therapeutics (MCRB) Posts Earnings Results, Beats Estimates By $0.03 EPS

Seres Therapeutics (NASDAQ:MCRB) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.03, Fidelity Earnings reports. Seres Therapeutics had a negative net margin of 264.31% and a negative return on equity of 256.24%. The company had revenue of $9.06 million for the quarter, compared to analyst estimates of $23.43 million.

MCRB stock traded down $0.48 during mid-day trading on Friday, hitting $8.40. The company had a trading volume of 155,488 shares, compared to its average volume of 100,299. The firm has a market cap of $330.04 million, a price-to-earnings ratio of -3.80 and a beta of 0.61. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.76 and a current ratio of 2.76. Seres Therapeutics has a 12 month low of $5.64 and a 12 month high of $11.35.

A number of research analysts recently weighed in on the stock. Zacks Investment Research raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 1st. Oppenheimer set a $16.00 price objective on shares of Seres Therapeutics and gave the stock a “buy” rating in a research report on Friday. BidaskClub raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday. Chardan Capital assumed coverage on shares of Seres Therapeutics in a research report on Monday, October 22nd. They issued a “buy” rating and a $15.00 price objective on the stock. Finally, ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. Seres Therapeutics has a consensus rating of “Hold” and a consensus target price of $13.81.

In other Seres Therapeutics news, insider John G. Aunins sold 14,279 shares of Seres Therapeutics stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $5.94, for a total value of $84,817.26. Following the sale, the insider now owns 103,811 shares of the company’s stock, valued at $616,637.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Roger Pomerantz sold 12,518 shares of Seres Therapeutics stock in a transaction dated Thursday, September 6th. The stock was sold at an average price of $9.10, for a total transaction of $113,913.80. Following the completion of the sale, the insider now directly owns 218,799 shares in the company, valued at approximately $1,991,070.90. The disclosure for this sale can be found here. In the last ninety days, insiders sold 69,634 shares of company stock worth $526,006. Insiders own 37.10% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Seres Therapeutics in the second quarter valued at approximately $117,000. Bank of America Corp DE raised its position in shares of Seres Therapeutics by 175.0% in the second quarter. Bank of America Corp DE now owns 36,489 shares of the biotechnology company’s stock valued at $314,000 after purchasing an additional 23,222 shares during the period. Chicago Equity Partners LLC bought a new stake in shares of Seres Therapeutics in the second quarter valued at approximately $415,000. Schwab Charles Investment Management Inc. raised its position in shares of Seres Therapeutics by 18.8% in the second quarter. Schwab Charles Investment Management Inc. now owns 117,255 shares of the biotechnology company’s stock valued at $1,009,000 after purchasing an additional 18,562 shares during the period. Finally, Schroder Investment Management Group raised its position in shares of Seres Therapeutics by 104.9% in the second quarter. Schroder Investment Management Group now owns 135,166 shares of the biotechnology company’s stock valued at $1,244,000 after purchasing an additional 69,205 shares during the period. 77.92% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://sportsperspectives.com/2018/11/10/seres-therapeutics-mcrb-posts-earnings-results-beats-estimates-by-0-03-eps.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. Its lead product candidate is SER-109, a bacterial spore ecology, which is in Phase III clinical study to treat multiply recurrent Clostridium difficile infection (CDI).

Further Reading: Technical Analysis

Earnings History for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply